SCHEMBL1827362

SCHEMBL1827362

CC(C)(C)OC(=O)N1CCC(c2ccc(F)cc2)C1

nearest known ligand 0.59

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PDE4B Q07343 1/20 0.58
RAB9A P51151 3/20 0.54
MAPT P10636 3/20 0.54
NPC1 O15118 2/20 0.54
ATM Q13315 1/20 0.53
POLB P06746 1/20 0.53
NAMPT P43490 1/20 0.52
MEN1 O00255 1/20 0.51
KMT2A Q03164 1/20 0.51
SMN1; SMN2 Q16637 2/20 0.50
JAK2 O60674 1/20 0.50
JAK3 P52333 1/20 0.50
PTK2 Q05397 1/20 0.50
ALDH1A1 P00352 1/20 0.50
GAA P10253 1/20 0.50
HDAC1 Q13547 1/20 0.49
HDAC2 Q92769 1/20 0.49
KDM4E B2RXH2 1/20 0.48
THRB P10828 1/20 0.48
RORC P51449 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1828228 1.00 PDE4B (0.58) PDE4BRAB9AMAPTNPC1ATM
SCHEMBL1827361 1.00 PDE4B (0.58) PDE4BRAB9AMAPTNPC1ATM
SCHEMBL22810473 0.93 PDE4B (0.52) PDE4BRAB9AMAPTNPC1ATM
SCHEMBL18805528 0.92 NAMPT (0.60) MAPTPOLBNAMPTMEN1KMT2A
SCHEMBL2594236 0.92 NAMPT (0.60) MAPTPOLBNAMPTMEN1KMT2A
SCHEMBL1239651 0.90 POLB (0.56) PDE4BMAPTPOLBNAMPTMEN1
SCHEMBL30712261 0.89 RORC (0.50) PDE4BPOLBNAMPTMEN1KMT2A
SCHEMBL18937651 0.88 PDE4B (0.60) PDE4BMAPTNAMPTKDM4ETHRB
SCHEMBL12321142 0.88 PDE4B (0.60) PDE4BRAB9AMAPTNPC1NAMPT
SCHEMBL1015283 0.86 PDE4B (0.58) PDE4BMAPTNAMPTALDH1A1GAA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-111936488-B Novel compounds for the treatment of parasitic infections 葛兰素史克知识产权开发有限公司 2023-06-27 CN disclosed
CN-111936488-A Novel compounds for the treatment of parasitic infections 葛兰素史克知识产权开发有限公司 2020-11-13 CN disclosed
CN-110167930-A ROR gamma modulators 百时美施贵宝公司 2019-08-23 CN disclosed
US-20110230419-A1 IAP BINDING COMPOUNDS NUEVOLUTION A/S (DK) 2011-09-22 US disclosed
EP-2318363-A1 HETEROCYCLIC DERIVATIVES AS IAP BINDING COMPOUNDS Nuevolution A/S (DK) 2011-05-11 EP disclosed
WO-2009152824-A1 HETEROCYCLIC DERIVATIVES AS IAP BINDING COMPOUNDS NUEVOLUTION A/S (DK) 2009-12-23 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110230419-A1 IAP BINDING COMPOUNDS BIRC5, BIRC7, BIRC3 PDE4B 2688/4885RAB9A 3513/4885MAPT 1455/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.